PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26377354-4	2016	Oral administration of Dex-5-ESA (equivalent to 10 mg 5-ASA/kg, twice a day) alleviated colonic injury and reduced MPO activity in the inflamed colon.	Mesalamine	54-59	myeloperoxidase	Rattus norvegicus	115-118	
24496680-13	2014	The colonic mucosal damage, both macroscopical and histological, was significantly relieved and the myeloperoxidase activity was markedly decreased in rats topically treated with 5-ASA compared with those treated with oral 5-ASA or Etiasa.	Mesalamine	179-184	myeloperoxidase	Rattus norvegicus	100-115	
26718757-6	2015	Treatment with 5-ASA or 1,25(OH)D3 ameliorated colitis by lowering CMDI (P=0.049, P=0.040, respectively), histological colonic damage score (P=0.010, P=0.005, respectively), and MPO activity (P=0.0003, P=0.0013, respectively) compared with the TNBS group.	Mesalamine	15-20	myeloperoxidase	Rattus norvegicus	178-181	
26718757-7	2015	Combined treatment with 5-ASA and 1,25(OH)D3 significantly decreased MPO activity (P=0.003).	Mesalamine	24-29	myeloperoxidase	Rattus norvegicus	69-72	
24764591-12	2004	With the topical application of mesalamine, the GSH and MDA levels and MPO activities were similar to those of the sham group.	Mesalamine	32-42	myeloperoxidase	Rattus norvegicus	71-74	
18703751-9	2008	MPO activity was decreased significantly in response to monotherapy with 5-ASA and each of the antioxidants plus 5-ASA when compared to TNBS.	Mesalamine	73-78	myeloperoxidase	Rattus norvegicus	0-3	
18703751-9	2008	MPO activity was decreased significantly in response to monotherapy with 5-ASA and each of the antioxidants plus 5-ASA when compared to TNBS.	Mesalamine	113-118	myeloperoxidase	Rattus norvegicus	0-3	
18703751-10	2008	alpha-Tocopherol plus 5-ASA, however, was the only treatment strategy that reduced significantly MPO activity below that recorded for 5-ASA alone.	Mesalamine	22-27	myeloperoxidase	Rattus norvegicus	97-100	
18703751-10	2008	alpha-Tocopherol plus 5-ASA, however, was the only treatment strategy that reduced significantly MPO activity below that recorded for 5-ASA alone.	Mesalamine	134-139	myeloperoxidase	Rattus norvegicus	97-100	
21153768-6	2011	The results showed that manifestation, colonic damage score and MPO activities of the rats treated with 5-ASA or/and rhITFs were improved, serum EGF production was augmented and expression of tissue NF-kappaB was down-regulated.	Mesalamine	104-109	myeloperoxidase	Rattus norvegicus	64-67	
19891583-9	2009	Mesalazine significantly improved changes in the length of the colon, tissue MPO activity, WBC, and the histological inflammation score as compared with DSS-induced colitis.	Mesalamine	0-10	myeloperoxidase	Rattus norvegicus	77-80	
18215658-4	2008	Intracolonic administration of 5-ASA (8, 25 and 75 mg/kg/day) dose-dependently reduced the TNBS-provoked macroscopic colonic inflammatory injury, myeloperoxidase (MPO) activity and TNF-alpha levels, while also dose-dependently increasing colonic heme oxygenase enzyme activity.	Mesalamine	31-36	myeloperoxidase	Rattus norvegicus	146-161	
18215658-4	2008	Intracolonic administration of 5-ASA (8, 25 and 75 mg/kg/day) dose-dependently reduced the TNBS-provoked macroscopic colonic inflammatory injury, myeloperoxidase (MPO) activity and TNF-alpha levels, while also dose-dependently increasing colonic heme oxygenase enzyme activity.	Mesalamine	31-36	myeloperoxidase	Rattus norvegicus	163-166	
16614956-10	2006	Myeloperoxidase activity was also reduced significantly by 5-aminosalicylic acid (P < 0.05) but not by hyperbaric oxygen.	Mesalamine	59-80	myeloperoxidase	Rattus norvegicus	0-15	
16461476-5	2006	RESULTS: Treatment of NaB, 5-ASA, and the combination improved diarrhoea, colonic damage score, and MPO activities, increased TFF3 mRNA expression, and decreased serum IL1beta production and tissue NFkappaB expression.	Mesalamine	27-32	myeloperoxidase	Rattus norvegicus	100-103	
12106976-10	2002	When 5-ASA was orally administered using chitosan capsules in TNBS-induced colitis rats, we found better therapeutic effects with 5-ASA than with a 5-ASA CMC suspension, as evaluated by the MPO activities, C/B ratio and the damage score.	Mesalamine	5-10	myeloperoxidase	Rattus norvegicus	190-193	
2563347-9	1989	5-Aminosalicylic acid, 4-ASA, and dapsone demonstrated a powerful inhibitory effect on the catalytic activity of myeloperoxidase, whereas all drugs were equally effective in scavenging HOCl.	Mesalamine	0-21	myeloperoxidase	Rattus norvegicus	113-128	
34712949-5	2021	Mesalamine and the HT diminished the length of the lesions formed in the colon, in addition to reducing the levels of myeloperoxidase and interleukin-1beta.	Mesalamine	0-10	myeloperoxidase	Rattus norvegicus	118-133	
2563347-11	1989	Our results indicate that inhibition of neutrophilic myeloperoxidase may be an important mechanism by which 5-ASA, 4-ASA, and dapsone attenuate FMLP-induced mucosal injury.	Mesalamine	108-113	myeloperoxidase	Rattus norvegicus	53-68	
33839254-7	2021	Molecular docking studies were conducted with four proteins (COX-2, MMP-9, TNF-alpha and MPO) to examine the interaction of mesalamine (MS) and mesalamine coumarin derivative (MS-CU).	Mesalamine	124-134	myeloperoxidase	Rattus norvegicus	89-92	
33319050-10	2020	In DSS-treated rats, 5-ASA, but not DKT, suppressed the MPO activity.	Mesalamine	21-26	myeloperoxidase	Rattus norvegicus	56-59